A New Tri-functional Product has arrived in South Africa
Innovation is a way of life
For us at Glenmark, innovation is not just a term, referring to scientific research and discovery.
It’s a way of life, it’s a means of creating a healthy, happy, ailment-free world.
All our actions are guided by innovative thinking and a strong set of values.
We practice innovation by finding new ways of doing things – big or small, thereby enabling us to enrich the lives of people across the globe.
Our R&D centers deliver innovation by combining cutting-edge technology, state-of-the-art infrastructure, and the brightest minds in the business.
Glenmark has its NCE, BioPharmaceutical, Clinical and Generics R&D center in India, Switzerland, and the US.
Glenmark’s R&D team of over 800 members is committed to discovering new possibilities for a better world.
Glenmark South Africa continues to work towards extending, developing, and focusing on its Dermatology Portfolio that has an integral role in developing medically niched support for the insights and the foresight of Dermatologists and skincare specialists in South Africa.
With all that said, Glenmark South Africa is proud to announce the:
1st to Market Generic of Imiquimod
Glentriz™ is indicated in the treatment of:
External Genital Warts (EGW)
Glentriz™ (imiquimod 5%) first-time recommendation by 14 global Anogenital wart experts
Worldwide approved for the treatment of EGW
Glentriz™ is as effective and safe as originator cream in the topical treatment of patients with external genital warts
Clearance rates for ECW with Glentriz™ 35-75%
Imiquimod was rated better in terms of overall satisfaction, convenience, time to clearance, and lack of associated pain than other EGW therapies
Actinic Keratosis (AK)
Reflectance confocal microscopy(RCM) studies have shown that field therapies such as imiquimod, can clear subclinical lesions
Guidelines for the Treatment of Actinic Keratosis
In patients with single AK lesions
In patients with multiple AK lesions
For immunocompromised patients with AK
Cosmetically superior to cryotherapy
Excellent cosmetic outcome reported
Better skin appearance reported
Superficial Basal Cell Carcinoma (sBCC)
Basal cell carcinoma (BCC) accounts for 80% of all skin cancers
Incidence BCC is increasing worldwide by up to 10% annually
Imiquimod has been used as a good alternative for surgery in sBCC
In 4256 patients with sBCC imiquimod 5% compared to other treatments:
Superior composite cure rate (p=0,0011)
Significantly greater complete response rate with imiquimod (p=0,001)
Significantly superior histological cure rate (p<0,001)
Join us for the Skin Cancer Clinical Overview Educational Webinar
Skin Cancer Clinical overview
Dr Irshad Essack
MBChB (Natal) FCDerm (SA)
Topic: Skin Cancer
Clinical overview of Actinic Keratosis and NMSC
Sunday, 24 October 2021 11:00 – 15:30 (GMT+2)
Want to know more about Glentriz™ and Glenmark?
Glenmark Pharmaceuticals South Africa
Glenmark Pharmaceuticals South Africa (Pty) Ltd was launched in December 2005. The company has been based in Midrand, Johannesburg since its inception. What started as a smaller organisation with only seven employees has now grown to be a productive, innovative company with more than 40 employees.
Since October 2018, Glenmark South Africa, under new and experienced leadership, has seen numerous promising developments in its existing and future portfolio, both in the dermatology and respiratory areas.
Expanding on the company’s specialty in the dermatology arena, Glenmark South Africa is pleased to announce that they are the first company to launch a generic Imiquimod Cream (5 %) in South Africa. This marks the 1st of a very strong dermatology pipeline to follow in the coming years.
Connect with Glenmark Pharmaceuticals
Address: 2nd Floor, Building D, Stoneridge Office Park, 8 Greenstone Place, Greenstone, Edenvale, Gauteng, 1609
Phone: +27(0) 11 564 3900
Fax: +27(0)86 600 6128